Shares of Pharvaris N.V. (PHVS) are soaring 5.22% in pre-market trading on Tuesday, following the company's release of its fourth-quarter earnings and 2024 financial results after market close on Monday. The significant uptick in stock price suggests that investors are responding positively to the biotech firm's financial disclosure.

Pharvaris N.V., a clinical-stage biopharmaceutical company focused on developing and commercializing novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, has been closely watched by investors interested in the biotech sector. The company's stock performance often reflects investor sentiment about its drug development progress and financial health.

While specific details of the earnings report were not immediately available, the market's positive reaction indicates that investors may be encouraged by aspects of Pharvaris's financial results or business updates. Shareholders and analysts will likely be scrutinizing the report for information on the company's cash position, burn rate, progress in clinical trials, and any forward-looking statements about potential milestones or regulatory submissions. As more details emerge from the earnings release, a clearer picture of Pharvaris N.V.'s financial standing and operational progress should become available to the market.